Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, tolerability and immunogenicity of gpASIT+TM with or without DnaK in hay fever patients
2011-004486-33Phase 2Terminated
- Sponsor
- TOOLS Life Science
- Start
- Oct 2011
- Modality
- Vaccines & Immunotherapeutics, Peptides
- Countries
- 1
01
Overview
Phase 2 trial of gpASIT+ in seasonal allergic rhinitis (SAR) and allergic rhinitis (AR) (2 arms), sponsored by TOOLS Life Science. Primary endpoint: Primary safety and tolerability endpoints. Started Oct 2011; status: terminated.
02
Drugs
gpASIT+
03
Conditions
seasonal allergic rhinitis (SAR)allergic rhinitis (AR)
Beyond the preview
Go deeper on 2011-004486-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004486-33.